Compare
Kestra Medical Technologies, Ltd. vs Iradimed Corp vs Anika Therapeutics, Inc. vs Orasure Technologies Inc
| Latest fiscal year | Kestra Medical Technologies, Ltd. KMTS | Iradimed Corp IRMD | Anika Therapeutics, Inc. ANIK | Orasure Technologies Inc OSUR |
|---|---|---|---|---|
| Year ended | 2026-04-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $95.13M | $83.81M | $112.82M | $115.02M |
| Revenue growth (YoY) | +59.0% | +14.4% | -5.9% | -38.1% |
| Gross margin | 51.4% | 76.7% | 56.6% | 41.9% |
| Operating margin | -141.6% | 31.2% | -9.8% | -62.6% |
| Net margin | -138.4% | 26.8% | -9.6% | -59.8% |
| Net income | -$131.61M | $22.48M | -$10.88M | -$68.73M |
| EPS (Diluted) | -$2.43 | $1.75 | -$0.76 | -$0.94 |
| Operating cash flow | -$81.70M | $24.95M | $11.19M | -$49.02M |
| Free cash flow | -$116.59M | $17.18M | $4.36M | -$53.22M |
| Cash & equivalents | $99.71M | $51.16M | $57.48M | $199.28M |
| Total assets | $358.46M | $108.78M | $190.27M | $403.17M |
| Total liabilities | $98.81M | $14.16M | n/a | $62.34M |
| Shareholders' equity | $259.66M | $94.62M | $143.47M | $340.83M |
| Return on year-end equity | -50.7% | 23.8% | -7.6% | -20.2% |
| Shares outstanding | 58.38M | 12.78M | 13.89M | 70.39M |
Revenue, most recent five fiscal years
| Fiscal year | Kestra Medical Technologies, Ltd. | Iradimed Corp | Anika Therapeutics, Inc. | Orasure Technologies Inc |
|---|---|---|---|---|
| Latest | $95.13M Ended 2026-04-30 | $83.81M Ended 2025-12-31 | $112.82M Ended 2025-12-31 | $115.02M Ended 2025-12-31 |
| 1 year earlier | $59.81M Ended 2025-04-30 | $73.24M Ended 2024-12-31 | $119.91M Ended 2024-12-31 | $185.83M Ended 2024-12-31 |
| 2 years earlier | $27.81M Ended 2024-04-30 | $65.56M Ended 2023-12-31 | $120.79M Ended 2023-12-31 | $405.47M Ended 2023-12-31 |
| 3 years earlier | n/a | $53.30M Ended 2022-12-31 | $113.83M Ended 2022-12-31 | $387.48M Ended 2022-12-31 |
| 4 years earlier | n/a | $41.81M Ended 2021-12-31 | $147.79M Ended 2021-12-31 | $233.67M Ended 2021-12-31 |